Susquehanna International Group’s Dermata Therapeutics DRMA Stock Holding History

Susquehanna International Group’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-84	Closed	-$20.9K	–	12193
2023 Q2	$20.9K	Buy	+84	New	+$22.9K	﹤0.01%	11628
2022 Q3	–	Sell	-5	Closed	-$7K	–	13352
2022 Q2	$7K	Buy	+5	New	+$10.3K	﹤0.01%	12566

Other funds holding DRMA

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's DRMA Position: Q3 2023 in Review

Susquehanna International Group sold out of Dermata Therapeutics (DRMA) in Q3 2023, closing a stake of 84 shares — an estimated $20.9K sold.

Susquehanna International Group first reported a position in DRMA in Q2 2022 and held it in 2 quarters. The position peaked at $20.9K in Q2 2023. 6 funds tracked by Wall St. Rank hold DRMA as of Q3 2023.

Susquehanna International Group reported no remaining Dermata Therapeutics position as of Q3 2023 after selling out during the quarter.
Susquehanna International Group sold 84 Dermata Therapeutics shares in Q3 2023, an estimated $20.9K.
Susquehanna International Group first reported a position in Dermata Therapeutics in Q2 2022 and held it in 2 quarters.
Susquehanna International Group's Dermata Therapeutics position peaked at $20.9K in Q2 2023.
6 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.